黄芪宗气方治疗冠心病合并心力衰竭患者的效果及对血管内皮功能影响

doi:10.3760/cma.j.cn441417-20250123-11002

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (11): 1770-1774.DOI: 10.3760/cma.j.cn441417-20250123-11002

黄芪宗气方治疗冠心病合并心力衰竭患者的效果及对血管内皮功能影响

刘谊¹ 韩宝华² 张悦³

¹陕西中医药大学第二附属医院心内二科陕西西府张氏内科脑病学术流派传承工作室，咸阳 712000；²陕西中医药大学第二附属医院心内科陕西西府张氏内科脑病学术流派传承工作室，咸阳 712000；³陕西中医药大学第一临床医学院中西医临床医学系，咸阳 712000

收稿日期:2025-01-23 出版日期:2025-06-01 发布日期:2025-06-12
通讯作者: 韩宝华，Email：1092548096@qq.com
基金资助:
国家自然科学基金（81774304）

The efficacy ofHuangqi ZongqiFormula in treating patients with coronary heart disease complicated with heart failure and its impact on vascular endothelial function

Liu Yi¹, Han Baohua², Zhang Yue³

¹Cardiology Department 2, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi Xifu Zhang's School of Cerebrovascular Medicine Academic Inheritance Studio, Xianyang 712000, China; ²Cardiology Department, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi Xifu Zhang's School of Cerebrovascular Medicine Academic Inheritance Studio, Xianyang 712000, China; ³Department of Traditional Chinese and Western Medicine Clinical Medicine, First Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang 712000, China

Received:2025-01-23 Online:2025-06-01 Published:2025-06-12
Contact: Han Baohua, Email: 1092548096@qq.com
Supported by:
National Natural Science Foundation of China (81774304)

摘要/Abstract

摘要：

目的　探讨黄芪宗气方治疗冠心病合并心力衰竭患者的效果及对血管内皮功能影响。方法　选取2021年10月至2024年10月陕西中医药大学第二附属医院收治的98例冠心病合并心力衰竭患者作为研究对象。采用随机数字表法，将患者分为中医组和常规组，每组49例。中医组男27例，女22例；年龄45～81（62.10±8.05）岁；冠心病病程4～13（8.43±2.09）年；心力衰竭病程1～5（2.61±0.70）年；纽约心脏病协会（NYHA）分级：Ⅱ级13例，Ⅲ级25例，Ⅳ级11例。常规组男25例，女24例；年龄44～82（63.20±8.78）岁；冠心病病程3～12（8.08±1.96）年；心力衰竭病程1～5（2.67±0.66）年；NYHA分级：Ⅱ级15例，Ⅲ级24例，Ⅳ级10例。常规组采用常规西医治疗，中医组在常规组基础上联合黄芪宗气方治疗。两组均连续治疗8周。比较两组临床疗效，治疗前后血管内皮功能（内皮素-1、一氧化氮）、心功能［左心室射血分数（LVEF）、左心室收缩末期内径（LVESD）、左心室舒张末期内径（LVEDD）、B型利钠肽（BNP）］、心力衰竭症状（Lee氏心力衰竭评分）及生活质量［明尼苏达心力衰竭生活质量问卷（MLHFQ）］。采用独立样本t检验、配对t检验和χ²检验进行统计学分析。结果　中医组治疗总有效率高于常规组［91.84%（45/49）比73.47%（36/49）］（P<0.05）。治疗后，中医组内皮素-1水平低于常规组［（43.98±3.30）ng/L比（51.31±3.88）ng/L］，一氧化氮水平高于常规组［（39.33±2.99）μmol/L比（35.15±1.37）μmol/L］（均P<0.05）；中医组LVEF高于常规组［（58.14±3.57）%比（55.06±4.43）%］，LVESD、LVEDD、BNP水平均低于常规组［（46.41±3.96）mm比（49.57±2.32）mm、（46.61±3.03）mm比（52.92±3.25）mm、（454.36±90.21）ng/L比（506.58±76.30）ng/L］（均P<0.05）；中医组Lee氏心力衰竭评分、MLHFQ评分均低于常规组［（7.47±1.60）分比（9.29±1.44）分、（38.12±4.60）分比（45.27±4.71）分］（均P<0.05）。结论　黄芪宗气方联合治疗冠心病合并心力衰竭效果较好，可改善血管内皮功能、心功能和心力衰竭症状，提高生活质量。

关键词:

冠心病, 心力衰竭, 黄芪宗气方, 血管内皮功能, 生活质量

Abstract:

Objective　To explore the efficacy of the Huangqi Zongqi Formula in treating patients with coronary heart disease combined with heart failure and its impact on vascular endothelial function. Methods　A total of 98 patients with coronary heart disease and heart failure who were admitted to the Second Affiliated Hospital of Shaanxi University of Chinese Medicine from October 2021 to October 2024 were selected as the research subjects. The patients were divided into the traditional Chinese medicine group and the conventional group using the random number table method, with 49 cases in each group. There were 27 males and 22 females in the traditional Chinese medicine group, aged 45-81 (62.10±8.05) years, course of coronary heart disease 4-13(8.43±2.09) years, course of heart failure 1-5 (2.61±0.70) years, New York Heart Association (NYHA) classification: 13 cases at grade Ⅱ, 25 cases at grade Ⅲ, and 11 cases at grade Ⅳ. There were 25 males and 24 females in the conventional group, aged 44-82 (63.20±8.78) years, course of coronary heart disease 3-12 (8.08±1.96) years, course of heart failure 1-5 (2.67±0.66) years, NYHA classification: 15 cases at grade Ⅱ, 24 cases at grade Ⅲ, and 10 cases at grade Ⅳ. The conventional group received conventional Western medical treatment, while the traditional Chinese medicine group was treated with the Huangqi Zongqi Formula in addition to the treatment provided by the conventional group. Both groups were treated continuously for 8 weeks. Compare the clinical efficacy of the two groups; vascular endothelial function (endothelin-1, nitric oxide), cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), B-type natriuretic peptide (BNP)], heart failure symptoms (Lee's heart failure score), and quality of life [Minnesota heart failure quality of life questionnaire (MLHFQ)] before and after treatment. Independent sample t test, paired t test, and χ² test were used for statistical analysis. Results　The total effective rate of the traditional Chinese medicine group was higher than that of the conventional group [91.84% (45/49) vs. 73.47% (36/49)] (P<0.05). After treatment, the level of endothelin-1 in the traditional Chinese medicine group was lower than that in the conventional group [(43.98±3.30) ng/L vs. (51.31±3.88) ng/L], and the level of nitric oxide was higher than that in the conventional group [(39.33±2.99) μmol/L vs. (35.15±1.37) μmol/L] (both P<0.05); the LVEF of the traditional Chinese medicine group was higher than that of the conventional group [(58.14±3.57)% vs. (55.06±4.43)%], while the LVESD, LVEDD and BNP levels were all lower in the traditional Chinese medicine group [(46.41±3.96) mm vs. (49.57±2.32) mm, (46.61±3.03) mm vs. (52.92±3.25) mm, (454.36±90.21) ng/L vs. (506.58±76.30) ng/L] (all P<0.05); the Lee's heart failure score and the MLHFQ score in the traditional Chinese medicine group were both lower than those in the conventional group [(7.47±1.60) points vs. (9.29±1.44) points, (38.12±4.60) points vs. (45.27±4.71) points] (both P<0.05). Conclusion　The Huangqi Zongqi Formula combined with other treatments for coronary heart disease complicated with heart failure has a better therapeutic effect. It can improve vascular endothelial function, cardiac function and symptoms of heart failure, and enhance the quality of life.

Key words: Coronary heart disease, Heart failure, Huangqi ZongqiFormula, Vascular endothelial function, Quality of life

刘谊韩宝华张悦. 黄芪宗气方治疗冠心病合并心力衰竭患者的效果及对血管内皮功能影响 [J]. 国际医药卫生导报, 2025, 31(11): 1770-1774.

Liu Yi, Han Baohua, Zhang Yue. The efficacy ofHuangqi ZongqiFormula in treating patients with coronary heart disease complicated with heart failure and its impact on vascular endothelial function[J]. International Medicine and Health Guidance News, 2025, 31(11): 1770-1774.

参考文献

[1]张玮畅,田晶,杨弘,等.冠心病合并慢性心力衰竭患者5年全因死亡生存分析与可解释性研究[J].中华疾病控制杂志,2023,27(4):373-378,391.DOI:10.16462/j.cnki.zhjbkz.2023.04.001.

[2]韩港飞,田晶,和紫铉,等.基于随机森林的冠心病合并心力衰竭患者PCI术后死亡风险预测研究[J].中华疾病控制杂志,2023,27(4):425-430.DOI:10.16462/j.cnki.zhjbkz.2023.04.009.

[3]王焱平,马金霞,王希瑞,等.复元活血汤联合针刺治疗气滞血瘀型冠心病合并慢性心力衰竭临床观察[J].中华中医药学刊,2025,43(4):197-200.DOI:10.13193/j.issn.1673-7717.2025.04.032.

[4]张娜,朱红利,李雪青,等.乌拉地尔联合贝那普利治疗冠心病合并心力衰竭患者的价值[J].分子诊断与治疗杂志,2024,16(6):1024-1027.DOI:10.3969/j.issn.1674-6929.2024.06.009.

[5]宋秋露,王保福,滕羽鸥,等.麝香保心丸联合曲美他嗪治疗冠心病合并心力衰竭疗效与安全性的系统评价[J].中西医结合心脑血管病杂志,2024,22(1):15-21.DOI:10.12102/j.issn.1672-1349.2024.01.003.

[6]中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.稳定性冠心病基层诊疗指南(实践版·2020)[J].中华全科医师杂志,2021,20(3):274-280.DOI:10.3760/cma.j.cn114798-20210120-00080.

[7]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.DOI:10.3760/cma.j.issn.0253-3758.2018.10.004.

[8]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:11-13.

[9]石远,曾丽,邓君进.大株红景天注射液联合沙库巴曲缬沙坦钠片治疗冠心病合并心力衰竭疗效研究[J].湖北中医药大学学报,2024,26(4):22-25.DOI:10.3969/j.issn.1008-987x.2024.04.05.

[10]陈宵宵,吴桂仙.中医健脾和胃法治疗冠心病慢性心力衰竭临床观察[J].中国中医药现代远程教育,2023,21(15):78-80.DOI:10.3969/j.issn.1672-2779.2023.15.026.

[11]朱燕波.慢性心功能不全QOL量表(MLHFQ)中文译本的计量心理学评价[D].北京:北京中医药大学,2003.

[12]徐雪梅,李凤娥,苏萍,等.温肾益心方辅助心脉隆注射液对老年冠心病合并心力衰竭患者的治疗效果[J].实用心脑肺血管病杂志,2024,32(10):100-104.DOI:10.12114/j.issn.1008-5971.2024.00.232.

[13]朱筱婧,喻正科,姜泱,等."天丹降压方"联合常规西药治疗冠心病合并心力衰竭64例临床研究[J].江苏中医药,2024,56(7):35-38.DOI:10.19844/j.cnki.1672-397X.2024.07.010.

[14]邵淑琳,余璐.稳心颗粒联合西药对气阴两虚型冠心病心力衰竭合并室性早搏患者心功能及血清N末端B型脑钠肽前体水平的影响[J].世界中西医结合杂志,2022,17(4):737-742.DOI:10.13935/j.cnki.sjzx.220417.

[15]姚燕鸽,张迎,王永刚,等."芪参强心方"联合常规疗法治疗气虚血瘀型冠心病慢性心力衰竭65例临床研究[J].江苏中医药,2022,54(4):40-43.DOI:10.19844/j.cnki.1672-397X.2022.04.015.

[16]Chen Q, Wang J, Sun L, et al. Mechanism of Astragalus membranaceus (Huangqi, HQ) for treatment of heart failure based on network pharmacology and molecular docking[J]. J Cell Mol Med, 2024, 28(10):e18331. DOI: 10.1111/jcmm.18331.

[17]Yun S, Oh J, Chu H, et al. Systematic review of preclinical studies on the efficacy and mechanisms of herbal medicines in post-myocardial infarction heart failure with reduced ejection fraction[J]. Medicina (Kaunas), 2024, 60(7):1101. DOI: 10.3390/medicina60071101.

[18]侯柯卉.益气活血、通阻养心方联合常规西药治疗心血瘀阻型冠心病慢性心力衰竭的临床研究[J].中西医结合心脑血管病杂志,2023,21(4):694-697.DOI:10.12102/j.issn.1672-1349.2023.04.021.

[19]殷昌斌,张健平,任慧,等.血清胆红素、NO、ET-1、VEGF水平联合检测对冠心病诊断价值[J].现代生物医学进展,2022,22(6):1121-1125.DOI:10.13241/j.cnki.pmb.2022.06.026.

[20]Del Buono MG, Moroni F, Montone RA, et al. Ischemic cardiomyopathy and heart failure after acute myocardial infarction[J]. Curr Cardiol Rep, 2022, 24(10):1505-1515. DOI: 10.1007/s11886-022-01766-6.

[21]张梦棣,梁鸿艺,时光喜,等.基于网络药理学和分子对接探讨黄芪补肾活血汤治疗乳腺癌的作用机制[J].西部中医药,2024,37(6):61-68.DOI:10.12174/j.issn.2096-9600.2024.06.16.

[22]曲信彦,高群,潘熠,等.基于网络药理学探讨黄芪、丹参治疗冠状动脉痉挛的活性成分与分子机制[J].中西医结合心脑血管病杂志,2022,20(15):2701-2709.DOI:10.12102/j.issn.1672-1349.2022.15.003.

[23]汪少卿,陆子华,方石虎,等.芪参益气滴丸在冠心病合并心力衰竭患者中的应用效果[J].中国当代医药,2023,30(35):65-69.DOI:10.3969/j.issn.1674-4721.2023.35.016.

[24]刘忠贵.参芪瓜蒌薤白半夏汤联合柴胡疏肝散治疗冠心病合并心力衰竭[J].中医学报,2019,34(2):388-390,403.DOI:10.16368/j.issn.1674-8999.2019.02.091.

[25]陈敏,何盈盈,左振芹.注射用益气复脉(冻干)治疗老年冠心病合并慢性心力衰竭伴低血压的临床观察[J].药物评价研究,2023,46(8):1734-1740.DOI:10.7501/j.issn.1674-6376.2023.08.017.

黄芪宗气方治疗冠心病合并心力衰竭患者的效果及对血管内皮功能影响

The efficacy ofHuangqi ZongqiFormula in treating patients with coronary heart disease complicated with heart failure and its impact on vascular endothelial function

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	魏欣妍魏文娟可易弘钱海兵. 基于授权赋能理论的健康教育在类风湿性关节炎患者中的应用效果 [J]. 国际医药卫生导报, 2025, 31(9): 1569-1573.
[2]	吝昭君杨洋高瑜. 三方角色标配引导护理模式在肺结核患者中的应用效果 [J]. 国际医药卫生导报, 2025, 31(9): 1574-1578.
[3]	韩鑫盛杰鑫任琳子于杰. 预测冠心病患者心肌缺血事件的冠状动脉CT血管成像定量参数分析 [J]. 国际医药卫生导报, 2025, 31(3): 365-370.
[4]	刘功艳王琳李传波韩克丽. 尼可地尔联合胺碘酮对冠心病心绞痛患者临床症状及血清相关细胞因子水平的影响 [J]. 国际医药卫生导报, 2025, 31(3): 382-386.
[5]	杜永波任毅张靖琨徐新松. 芪苈强心胶囊佐治心力衰竭合并心房颤动阳虚水泛证的临床效果 [J]. 国际医药卫生导报, 2025, 31(3): 387-391.
[6]	王荣荣张进. 三一照护管理模式对2型糖尿病患者血糖、自我管理水平及生活质量的影响 [J]. 国际医药卫生导报, 2025, 31(2): 198-202.
[7]	解晖赵珊庞晖冯萌李娜张艳利. 血管内皮功能与DN患者并发缺血性心脑血管病的关系 [J]. 国际医药卫生导报, 2025, 31(12): 2011-2016.
[8]	徐丹赵莹高亭. 华法林、阿司匹林、氯吡格雷三联治疗心房颤动患者的效果及对凝血因子的影响 [J]. 国际医药卫生导报, 2025, 31(12): 2027-2032.
[9]	王效邓智平张习凡李阳张彧. 多学科协作对乳腺癌化疗致周围神经病变患者的作用 [J]. 国际医药卫生导报, 2025, 31(12): 2093-2097.
[10]	郭婉贞刘向阳朱建欣. “互联网+”模式护理干预对食管癌化疗患者心理弹性水平的影响 [J]. 国际医药卫生导报, 2025, 31(12): 2098-2103.
[11]	胡人月曹晓媚夏雪艳. 尿酸/高密度脂蛋白胆固醇比值预测老年慢性心力衰竭患者主要心血管不良事件的价值 [J]. 国际医药卫生导报, 2025, 31(11): 1775-1779.
[12]	刘馨玉石永朋高渊. 血清TSP-1、Apela水平在冠状动脉粥样硬化性心脏病慢性心力衰竭患者中的表达及意义 [J]. 国际医药卫生导报, 2025, 31(11): 1784-1790.
[13]	金兴山杨莉. 地奥心血康胶囊联合地尔硫卓对冠心病心绞痛患者临床症状及血清相关细胞因子水平的影响分析 [J]. 国际医药卫生导报, 2025, 31(11): 1791-1795.
[14]	叶晓慧韩金桃王迈瑞. 基于“互联网+”运动康复护理在慢性心力衰竭患者中的应用 [J]. 国际医药卫生导报, 2025, 31(11): 1796-1800.
[15]	季增辉曲辅政韩佳琪张娟于养生程浩然. 环状RNA在心力衰竭中的研究进展 [J]. 国际医药卫生导报, 2025, 31(11): 1816-1819.